查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1427058

全球超重治療市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按治療、按分銷管道、按地區

Overweight Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 245 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球超重治療市場規模是由多種因素推動的，包括病態肥胖人群意識的提高、監管機構和藥品製造商之間的戰略聯盟以及肥胖相關疾病患病率的上升。我們正在實現強勁增長。 預計2024年該市場價值將達到340億美元，到2031年底預計將達到驚人的740億美元。

COVID-19 大流行凸顯了肥胖者對各種健康併發症的脆弱性，促使對超重治療解決方案的需求激增。 美國心臟協會強調，心血管疾病、第二型糖尿病、血脂異常、睡眠障礙和高血壓等疾病與肥胖有直接關係。 這種意識導致尋求減肥解決方案的個人越來越多地轉向營養補充劑、藥物、運動和手術幹預，例如抽脂。

美國食品藥物管理局 (FDA) 與藥品製造商之間的合作顯著加快了創新超重治療產品的審批流程。 2012年頒布的美國FDA安全創新法案為藥品製造商提供了針對嚴重疾病開發新療法的誘因，並為市場發展創造了有利的環境。 這種監管支持，加上已開發國家久坐生活方式的盛行，預計將在未來幾年推動全球超重治療市場的發展。

儘管成長軌跡充滿希望，但市場仍面臨藥物開發和手術成本高昂等挑戰。 研發和臨床試驗所需的高額財務投資是市場擴張的障礙。 此外，與某些藥物相關的安全問題導致產品召回和撤回，從而降低了消費者信心並阻礙了市場成長。

本報告考察了全球超重治療市場，並提供了市場概述，包括按治療趨勢、分銷管道、區域以及進入市場的公司的競爭趨勢。

目錄

第 1 章執行摘要

第2章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第 3 章 2018-2031 年全球超重治療市場展望

  • 2018-2031 年全球超重治療市場前景（依治療方式分類）、價值（十億美元）
  • 2018-2031 年全球超重治療市場展望，依通路劃分，價值（十億美元）
  • 2018-2031 年全球超重治療市場前景（按地區、價值（十億美元））

第 4 章北美超重治療市場展望，2018-2031

第5章歐洲超重治療市場前景，2018-2031

第 6 章亞太地區超重治療市場展望，2018-2031

第 7 章拉丁美洲超重治療市場展望，2018-2031

第 8 章中東與非洲超重治療市場展望，2018-2031

第9章競爭態勢

  • 按產品和分銷管道劃分的熱圖
  • 2022 年公司市佔率分析
  • 競爭對手儀表板
  • 公司簡介
    • Novo Nordisk A/S
    • VIVUS LLC
    • AstraZeneca
    • Currax Pharmaceuticals LLC
    • Spansules Pharmatech Pvt Ltd
    • Atkins Nutritional Inc
    • Apollo Endosurgery, Inc
    • Herbalife Nutrition Ltd.
    • SMP Nutra
    • Allurion Technologies
    • ReShape Lifesciences, Inc

第10章 附錄

簡介目錄

Growing Awareness and Strategic Partnerships Drive Demand for Overweight Treatment Solutions

The global overweight treatment market is witnessing robust growth, fueled by a combination of factors including increased awareness among the morbidly obese population, strategic collaborations between regulatory bodies and drug manufacturers, and the rising prevalence of obesity-related diseases. According to the latest report by Fairfield Market Research, the market, valued at US$ 34 billion in 2024, is expected to reach a staggering valuation of US$ 74 billion by the end of 2031.

Increasing Awareness among the Morbidly Obese Population

The COVID-19 pandemic has underscored the vulnerability of obese individuals to various health complications, prompting a surge in demand for overweight treatment solutions. Diseases such as cardiovascular ailments, type II diabetes, dyslipidemia, sleep disorders, and hypertension are directly linked to obesity, as highlighted by the American Heart Association. This awareness has led to a growing inclination towards nutrition supplements, drug treatments, exercise, and surgical interventions like liposuction among individuals seeking weight loss solutions.

Cooperation between Regulatory Bodies and Drug Manufacturers

The collaboration between the U.S. Food and Drug Administration (FDA) and drug manufacturers has significantly expedited the approval process for innovative overweight treatment products. The USFDA Safety Innovations Act of 2012 has incentivized manufacturers to develop novel therapies for serious medical conditions, thereby fostering a conducive environment for market growth. This regulatory support, coupled with the increasing prevalence of sedentary lifestyles in developed nations, is expected to propel the global overweight treatment market forward in the coming years.

Challenges Hindering Market Progress

Despite the promising growth trajectory, the market faces challenges such as the high cost of drug development and surgical procedures. The substantial financial investment required for research, development, and clinical trials poses a barrier to market expansion. Moreover, safety concerns associated with certain drugs have led to product recalls and withdrawals, dampening consumer confidence and hindering market growth.

Country-wise Insights: Opportunities Abound in Key Markets

United States: With a significant share in the North American market, the U.S. remains a lucrative hub for overweight treatment solutions. The rising incidence of obesity-related diseases and increasing awareness among consumers are driving the demand for weight management resources, including dietary supplements and lifestyle modifications.

Germany: The European overweight treatment market is witnessing steady growth, with Germany emerging as a key player. High prevalence of obesity-related diseases, coupled with collaborative efforts by organizations like the German Obesity Alliance, is driving market expansion, particularly in the area of obesity treatment centers.

China: Economic growth and changing lifestyle habits have contributed to a surge in obesity rates in China. The market for overweight treatment solutions is poised for rapid expansion, with a shift towards modern interventions such as medications and surgery from traditional herbal remedies.

India: India presents immense growth opportunities in the overweight treatment market, fueled by rising obesity rates and government initiatives promoting healthy lifestyles. Initiatives such as the Ayushman Bharat Scheme and the inclusion of bariatric surgery under insurance coverage are expected to drive market growth in the country.

Competitive Landscape: Key Players Driving Innovation

Leading companies in the overweight treatment market are continuously innovating to maintain their competitive edge. Strategic initiatives such as new product launches, portfolio upgrades, and clinical research activities are commonplace. Additionally, consolidation activities through collaborations and acquisitions are enabling players to strengthen their market presence and expand their product offerings.

Key Companies Profiled:

  • Novo Nordisk A/S
  • VIVUS LLC
  • AstraZeneca
  • Currax Pharmaceuticals LLC
  • Spansules Pharmatech Pvt Ltd
  • Atkins Nutritional Inc
  • Apollo Endosurgery, Inc
  • Herbalife Nutrition Ltd.
  • SMP Nutra
  • Allurion Technologies
  • ReShape Lifesciences, Inc
  • Bariatric Solutions GmbH
  • Silimed
  • ENDALIS
  • Districlass Medical
  • Medtronic.

Key Segments Covered in Overweight Treatment Industry Research

Overweight Treatment Market by Treatment:

  • Drug Treatment
    • Bupropion and Naltrexone
    • Orlistat
    • Phentermine and Topiramate
    • Liraglutide
  • Others
  • Supplements
  • Medical Devices / Implants
    • Gastric Balloons
    • Gastric Bands
    • Stapling Devices

Overweight Treatment Market by Distribution Channel:

  • Institutional Sales
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
  • Retail Sales
    • Retail Pharmacy
    • Drug Stores
    • Supermarkets / Hypermarkets
    • Health & Beauty Stores
  • Online Sales

Overweight Treatment Market by Region:

  • North America Overweight Treatment Market
  • Latin America Overweight Treatment Market
  • Europe Overweight Treatment Market
  • South Asia Overweight Treatment Market
  • East Asia Overweight Treatment Market
  • Oceania Overweight Treatment Market
  • Middle East & Africa Overweight Treatment Market

Table of Contents

1. Executive Summary

  • 1.1. Global Overweight Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Overweight Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
        • 3.1.1.1.1. Drug Treatment
          • 3.1.1.1.1.1. Bupropion and Naltrexone
          • 3.1.1.1.1.2. Orlistat
          • 3.1.1.1.1.3. Phentermine and Topiramate
          • 3.1.1.1.1.4. Liraglutide
        • 3.1.1.1.2. Others
        • 3.1.1.1.3. Supplements
        • 3.1.1.1.4. Medical Devices / Implants
          • 3.1.1.1.4.1. Gastric Balloons
          • 3.1.1.1.4.2. Gastric Bands
          • 3.1.1.1.4.3. Stapling Devices
  • 3.2. Global Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Institutional Sales
        • 3.2.1.1.1. Hospitals
        • 3.2.1.1.2. Specialty Clinics
        • 3.2.1.1.3. Ambulatory Surgical Centers
      • 3.2.1.2. Retail Sales
        • 3.2.1.2.1. Retail Pharmacy
        • 3.2.1.2.2. Drug Stores
        • 3.2.1.2.3. Supermarkets / Hypermarkets
        • 3.2.1.2.4. Health & Beauty Stores
      • 3.2.1.3. Online Sales
  • 3.3. Global Overweight Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Overweight Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
        • 4.1.1.1.1. Drug Treatment
          • 4.1.1.1.1.1. Bupropion and Naltrexone
          • 4.1.1.1.1.2. Orlistat
          • 4.1.1.1.1.3. Phentermine and Topiramate
          • 4.1.1.1.1.4. Liraglutide
        • 4.1.1.1.2. Others
        • 4.1.1.1.3. Supplements
        • 4.1.1.1.4. Medical Devices / Implants
          • 4.1.1.1.4.1. Gastric Balloons
          • 4.1.1.1.4.2. Gastric Bands
          • 4.1.1.1.4.3. Stapling Devices
  • 4.2. North America Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Institutional Sales
        • 4.2.1.1.1. Hospitals
        • 4.2.1.1.2. Specialty Clinics
        • 4.2.1.1.3. Ambulatory Surgical Centers
      • 4.2.1.2. Retail Sales
        • 4.2.1.2.1. Retail Pharmacy
        • 4.2.1.2.2. Drug Stores
        • 4.2.1.2.3. Supermarkets / Hypermarkets
        • 4.2.1.2.4. Health & Beauty Stores
      • 4.2.1.3. Online Sales
  • 4.3. North America Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Overweight Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
        • 5.1.1.1.1. Drug Treatment
          • 5.1.1.1.1.1. Bupropion and Naltrexone
          • 5.1.1.1.1.2. Orlistat
          • 5.1.1.1.1.3. Phentermine and Topiramate
          • 5.1.1.1.1.4. Liraglutide
        • 5.1.1.1.2. Others
        • 5.1.1.1.3. Supplements
        • 5.1.1.1.4. Medical Devices / Implants
          • 5.1.1.1.4.1. Gastric Balloons
          • 5.1.1.1.4.2. Gastric Bands
          • 5.1.1.1.4.3. Stapling Devices
  • 5.2. Europe Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Institutional Sales
        • 5.2.1.1.1. Hospitals
        • 5.2.1.1.2. Specialty Clinics
        • 5.2.1.1.3. Ambulatory Surgical Centers
      • 5.2.1.2. Retail Sales
        • 5.2.1.2.1. Retail Pharmacy
        • 5.2.1.2.2. Drug Stores
        • 5.2.1.2.3. Supermarkets / Hypermarkets
        • 5.2.1.2.4. Health & Beauty Stores
      • 5.2.1.3. Online Sales
  • 5.3. Europe Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Overweight Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
        • 6.1.1.1.1. Drug Treatment
          • 6.1.1.1.1.1. Bupropion and Naltrexone
          • 6.1.1.1.1.2. Orlistat
          • 6.1.1.1.1.3. Phentermine and Topiramate
          • 6.1.1.1.1.4. Liraglutide
        • 6.1.1.1.2. Others
        • 6.1.1.1.3. Supplements
        • 6.1.1.1.4. Medical Devices / Implants
          • 6.1.1.1.4.1. Gastric Balloons
          • 6.1.1.1.4.2. Gastric Bands
          • 6.1.1.1.4.3. Stapling Devices
  • 6.2. Asia Pacific Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Institutional Sales
        • 6.2.1.1.1. Hospitals
        • 6.2.1.1.2. Specialty Clinics
        • 6.2.1.1.3. Ambulatory Surgical Centers
      • 6.2.1.2. Retail Sales
        • 6.2.1.2.1. Retail Pharmacy
        • 6.2.1.2.2. Drug Stores
        • 6.2.1.2.3. Supermarkets / Hypermarkets
        • 6.2.1.2.4. Health & Beauty Stores
      • 6.2.1.3. Online Sales
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Overweight Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
        • 7.1.1.1.1. Drug Treatment
          • 7.1.1.1.1.1. Bupropion and Naltrexone
          • 7.1.1.1.1.2. Orlistat
          • 7.1.1.1.1.3. Phentermine and Topiramate
          • 7.1.1.1.1.4. Liraglutide
        • 7.1.1.1.2. Others
        • 7.1.1.1.3. Supplements
        • 7.1.1.1.4. Medical Devices / Implants
          • 7.1.1.1.4.1. Gastric Balloons
          • 7.1.1.1.4.2. Gastric Bands
          • 7.1.1.1.4.3. Stapling Devices
  • 7.2. Latin America Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Institutional Sales
        • 7.2.1.1.1. Hospitals
        • 7.2.1.1.2. Specialty Clinics
        • 7.2.1.1.3. Ambulatory Surgical Centers
      • 7.2.1.2. Retail Sales
        • 7.2.1.2.1. Retail Pharmacy
        • 7.2.1.2.2. Drug Stores
        • 7.2.1.2.3. Supermarkets / Hypermarkets
        • 7.2.1.2.4. Health & Beauty Stores
      • 7.2.1.3. Online Sales
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Overweight Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
        • 8.1.1.1.1. Drug Treatment
          • 8.1.1.1.1.1. Bupropion and Naltrexone
          • 8.1.1.1.1.2. Orlistat
          • 8.1.1.1.1.3. Phentermine and Topiramate
          • 8.1.1.1.1.4. Liraglutide
        • 8.1.1.1.2. Others
        • 8.1.1.1.3. Supplements
        • 8.1.1.1.4. Medical Devices / Implants
          • 8.1.1.1.4.1. Gastric Balloons
          • 8.1.1.1.4.2. Gastric Bands
          • 8.1.1.1.4.3. Stapling Devices
  • 8.2. Middle East & Africa Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Institutional Sales
        • 8.2.1.1.1. Hospitals
        • 8.2.1.1.2. Specialty Clinics
        • 8.2.1.1.3. Ambulatory Surgical Centers
      • 8.2.1.2. Retail Sales
        • 8.2.1.2.1. Retail Pharmacy
        • 8.2.1.2.2. Drug Stores
        • 8.2.1.2.3. Supermarkets / Hypermarkets
        • 8.2.1.2.4. Health & Beauty Stores
      • 8.2.1.3. Online Sales
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Product vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2022
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novo Nordisk A/S
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. VIVUS LLC
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. AstraZeneca
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Currax Pharmaceuticals LLC
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Spansules Pharmatech Pvt Ltd
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Atkins Nutritional Inc
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Apollo Endosurgery, Inc
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Herbalife Nutrition Ltd.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. SMP Nutra
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Allurion Technologies
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Therapy Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. ReShape Lifesciences, Inc
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Therapy Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations